NL195022C - Antilichamen en actieve fragmenten daarvan die dienen voor het hiermee versterken van B-celuitbreiding. - Google Patents
Antilichamen en actieve fragmenten daarvan die dienen voor het hiermee versterken van B-celuitbreiding. Download PDFInfo
- Publication number
- NL195022C NL195022C NL8701371A NL8701371A NL195022C NL 195022 C NL195022 C NL 195022C NL 8701371 A NL8701371 A NL 8701371A NL 8701371 A NL8701371 A NL 8701371A NL 195022 C NL195022 C NL 195022C
- Authority
- NL
- Netherlands
- Prior art keywords
- cells
- cell
- bcgf
- antibodies
- mab
- Prior art date
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title claims description 213
- 230000010261 cell growth Effects 0.000 title claims description 32
- 239000012634 fragment Substances 0.000 title claims description 21
- 101710165474 Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 claims description 77
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 77
- 210000004027 cell Anatomy 0.000 claims description 74
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 102000005962 receptors Human genes 0.000 claims description 26
- 108020003175 receptors Proteins 0.000 claims description 26
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 230000006870 function Effects 0.000 claims description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 7
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 6
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003305 autocrine Effects 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims 2
- 230000004073 interleukin-2 production Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 1
- 150000001875 compounds Chemical group 0.000 claims 1
- 238000011503 in vivo imaging Methods 0.000 claims 1
- 230000009131 signaling function Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 38
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 21
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 21
- 230000000284 resting effect Effects 0.000 description 19
- 102000000588 Interleukin-2 Human genes 0.000 description 18
- 108010002350 Interleukin-2 Proteins 0.000 description 18
- 230000004913 activation Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 102000000589 Interleukin-1 Human genes 0.000 description 13
- 108010002352 Interleukin-1 Proteins 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000010166 immunofluorescence Methods 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 9
- 229940104230 thymidine Drugs 0.000 description 9
- 230000003844 B-cell-activation Effects 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 230000022131 cell cycle Effects 0.000 description 8
- 230000018199 S phase Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 230000010190 G1 phase Effects 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 101000984569 Enterobacteria phage T4 Baseplate tail-tube junction protein gp54 Proteins 0.000 description 5
- 101000748871 Escherichia phage Mu Translational activator com Proteins 0.000 description 5
- 101001011353 Escherichia phage N15 SAR-endolysin Proteins 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- 101000979735 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial Proteins 0.000 description 4
- 102100024975 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000002998 immunogenetic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000002741 palatine tonsil Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 230000004940 costimulation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 2
- 101710129514 B-cell differentiation antigen CD72 Proteins 0.000 description 2
- 102000011412 Complement 3d Receptors Human genes 0.000 description 2
- 108010023729 Complement 3d Receptors Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 230000035519 G0 Phase Effects 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000189662 Calla Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100020941 Interleukin-4 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000009028 cell transition Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000007974 regulation of B cell activation Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 238000013374 right angle light scattering Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87388486A | 1986-06-13 | 1986-06-13 | |
| US87388486 | 1986-06-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL8701371A NL8701371A (nl) | 1988-01-04 |
| NL195022C true NL195022C (nl) | 2003-06-18 |
Family
ID=25362524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8701371A NL195022C (nl) | 1986-06-13 | 1987-06-12 | Antilichamen en actieve fragmenten daarvan die dienen voor het hiermee versterken van B-celuitbreiding. |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPH0762040B2 (de) |
| KR (1) | KR910004100B1 (de) |
| AT (1) | AT398437B (de) |
| AU (1) | AU617087B2 (de) |
| BE (1) | BE1000587A4 (de) |
| CA (1) | CA1338781C (de) |
| CH (1) | CH676600A5 (de) |
| CY (1) | CY1681A (de) |
| DE (1) | DE3719398C2 (de) |
| DK (1) | DK173940B1 (de) |
| FR (1) | FR2607136B1 (de) |
| GB (1) | GB2191494B (de) |
| GR (1) | GR870930B (de) |
| HK (1) | HK10293A (de) |
| IE (1) | IE60486B1 (de) |
| IL (1) | IL82841A (de) |
| IT (1) | IT1208649B (de) |
| LU (1) | LU86919A1 (de) |
| NL (1) | NL195022C (de) |
| PT (1) | PT85073B (de) |
| SE (1) | SE504675C2 (de) |
| SG (1) | SG118992G (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| CO4600681A1 (es) | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443427A (en) * | 1982-06-21 | 1984-04-17 | Sidney Farber Cancer Institute, Inc. | Monoclonal antibody |
| EP0117705A3 (de) * | 1983-02-24 | 1985-09-25 | The Regents Of The University Of California | Monocyten und Blastzellen spezifischer monoklonaler Antikörper |
| FR2547731A1 (fr) * | 1983-06-27 | 1984-12-28 | Centre Nat Rech Scient | Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro |
| US4585742A (en) * | 1983-12-14 | 1986-04-29 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibody with specificity to human small cell carcinoma and use thereof |
-
1987
- 1987-06-10 BE BE8700641A patent/BE1000587A4/fr not_active IP Right Cessation
- 1987-06-10 IL IL82841A patent/IL82841A/xx not_active IP Right Cessation
- 1987-06-11 GB GB8713650A patent/GB2191494B/en not_active Expired - Lifetime
- 1987-06-11 DE DE3719398A patent/DE3719398C2/de not_active Expired - Lifetime
- 1987-06-12 PT PT85073A patent/PT85073B/pt unknown
- 1987-06-12 KR KR1019870005969A patent/KR910004100B1/ko not_active Expired
- 1987-06-12 NL NL8701371A patent/NL195022C/nl not_active IP Right Cessation
- 1987-06-12 JP JP62146811A patent/JPH0762040B2/ja not_active Expired - Lifetime
- 1987-06-12 IE IE156387A patent/IE60486B1/en not_active IP Right Cessation
- 1987-06-12 CA CA000539506A patent/CA1338781C/en not_active Expired - Lifetime
- 1987-06-12 DK DK198703022A patent/DK173940B1/da not_active IP Right Cessation
- 1987-06-12 SE SE8702463A patent/SE504675C2/sv not_active IP Right Cessation
- 1987-06-12 LU LU86919A patent/LU86919A1/fr unknown
- 1987-06-12 FR FR878708245A patent/FR2607136B1/fr not_active Expired
- 1987-06-12 IT IT8720899A patent/IT1208649B/it active
- 1987-06-15 CH CH2240/87A patent/CH676600A5/de not_active IP Right Cessation
- 1987-06-15 GR GR870930A patent/GR870930B/el unknown
- 1987-06-15 AU AU74214/87A patent/AU617087B2/en not_active Expired
- 1987-06-15 AT AT0151387A patent/AT398437B/de not_active IP Right Cessation
-
1992
- 1992-11-10 SG SG1189/92A patent/SG118992G/en unknown
-
1993
- 1993-02-11 HK HK102/93A patent/HK10293A/xx not_active IP Right Cessation
- 1993-10-10 CY CY1681A patent/CY1681A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ledbetter et al. | Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression. | |
| US5182368A (en) | Ligands and methods for augmenting B-cell proliferation | |
| US5786456A (en) | Bp 50-specific antibodies and fragments thereof | |
| Clark et al. | Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. | |
| Perussia et al. | Human natural killer cells analyzed by B73. 1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73. 1. | |
| Fleischer | A novel pathway of human T cell activation via a 103 kD T cell activation antigen. | |
| US5601819A (en) | Bispecific antibodies for selective immune regulation and for selective immune cell binding | |
| Yokochi et al. | B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. | |
| Ledbetter et al. | Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40). | |
| Perussia et al. | A human NK and K cell subset shares with cytotoxic T cells expression of the antigen recognized by antibody OKT8. | |
| Smith et al. | Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1 | |
| Harada et al. | Identification of early plasma cells in peripheral blood and their clinical significance | |
| Ledbetter et al. | Surface phenotype and function of tonsillar germinal center and mantle zone B cell subsets | |
| Degos et al. | Syndrome of neutrophil agranulocytosis, hypogammaglobulinemia, and thymoma | |
| JPH0638789A (ja) | 抗ｃｄ３刺激ｔ細胞の増殖を阻害するハイブリドーマおよびモノクローナル抗体 | |
| Kirsch et al. | The pattern of expression of CD147/neurothelin during human T‐cell ontogeny as defined by the monoclonal antibody 8D6 | |
| Seiler et al. | Monoclonal antibodies: their chemistry, functions, and possible uses | |
| NL195022C (nl) | Antilichamen en actieve fragmenten daarvan die dienen voor het hiermee versterken van B-celuitbreiding. | |
| de Palazzo et al. | Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fcγ receptor expressed by human large granular lymphocytes | |
| Yamamoto et al. | Induction of Tac antigen and proliferation of myeloid leukemic cells by ATL-derived factor: comparison with other agents that promote differentiation of human myeloid or monocytic leukemic cells | |
| US5028424A (en) | Antibodies to receptor and antigen for natural killer and non-specific cytotoxic cells | |
| Jewett et al. | Pentoxifylline suppresses interleukin-2-mediated activation of immature human natural killer cells by inhibiting endogenous tumor necrosis factor-alpha secretion | |
| EP0325489B1 (de) | Leu-23: Monoclonaler Antikörper zur Überwachung von Leukozyten-Aktivierung | |
| Morikawa et al. | Functional analysis of clonally expanded CD8, TCRγδ T cells in a patient with chronic T-gamma lymphoproliferative disease | |
| Takeuchi et al. | Interleukin 1 (IL-1α and IL-1β) induces differentiation/activation of B cell chronic lymphoid leukemia cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| NP1 | Patent granted (not automatically) | ||
| V4 | Discontinued because of reaching the maximum lifetime of a patent |
Effective date: 20070612 |